OHSU researchers identify promising next-generation cancer treatment

Chemistry discovery points to next generation inhibitors of PARP-1, a critical target in ovarian, breast and prostate cancers

By Joe Rojas-Burke February 10, 2023 Portland, Oregon

Lea esta página en español

Downloads

Michael Cohen, Ph.D. (OHSU)

Moriah Arnold, Ph.D. (OHSU)

Chemistry discovery critical in cancer treatment

Michael Cohen, Ph.D., in his lab with Moriah Arnold, an M.D./Ph.D. student and co-author of the study unveiling a new class of PARP-1 inhibitors. (OHSU/Christine Torres Hicks)

Michael Cohen and Moriah Arnold

Michael Cohen, Ph.D., and Moriah Arnold, an M.D./Ph.D. student and co-author of the study unveiling a new class of PARP-1 inhibitors, in the Cohen lab inside the OHSU Biomedical Research Building on Friday, Feb. 10, 2023. (OHSU/Christine Torres Hicks)

Model - Cohen Lab

Michael Cohen, Ph.D., holds a molecular model. The red dot represents a small molecule inhibitor, which his team designed, in the binding pocket of its target protein. (OHSU/Christine Torres Hicks)

Moriah Arnold and Michael Cohen

Michael Cohen, Ph.D., and Moriah Arnold, an M.D./Ph.D. student and co-author of the study unveiling a new class of PARP-1 inhibitors, stand outside the OHSU Biomedical Research Building on Friday, Feb. 10, 2023. (OHSU/Christine Torres Hicks)

OHSU researchers identify promising next-generation cancer treatment

Michael Cohen, Ph.D., in his lab with Moriah Arnold, a student in the OHSU Graduate Program in Biomedical Sciences, School of Medicine. (OHSU/Christine Torres Hicks)

Michael Cohen Lab

A microscope view of tumor-initiating cells used in the Cohen lab. (OHSU/Christine Torres Hicks)